Figure.

Effects of A) Rv0678 RAVs in baseline isolates and Rv0678 RAVs acquired during treatment, and B) baseline BDQ MIC for wild-type and Rv0678 baseline isolates on sputum culture conversion rates at Week 24 (no overruling for discontinuation) for BDQ-treated patients in the Phase 2b studies, TMC207-C208 Stage 2 and TMC207-C209. Sputum culture conversion was defined as two consecutive negative cultures from sputum samples collected at least 25 days apart. All intermediate cultures had to be negative as well. This condition was overruled when followed by a confirmed positive result, defined as two consecutive visits with positive sputum results, not taking into account intermittent missing/contaminated results. In the no-overrulingfor-discontinuation analysis, discontinuation information was not taken into account (patients who converted, then discontinued afterwards were considered as converted). In A), the numbers in the bars represent the actual number of isolates in each category (Week 24, P = 0.52 for culture conversion rate with baseline wild-type isolates vs. baseline Rv0678 RAVs; Week 24, P < 0.0001 for culture conversion rate with post-baseline wild type isolates vs. post-baseline Rv0678 RAVs). In B), the numbers in the bars represent the actual number of isolates in each category. RAV = resistance-associated variant; BDQ = bedaquiline; MIC = minimal inhibitory concentration.